Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2001 December;13(4) > Minerva Biotecnologica 2001 December;13(4):313-23





A Journal on Biotechnology and Molecular Biology

Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246




Minerva Biotecnologica 2001 December;13(4):313-23


language: English

The devel­op­ment and eco­nom­ic ­impact of bio­tech­nol­o­gy espe­cial­ly regard­ing the bio­med­i­cal sec­tor with­in ­Europe’s ­main indus­tri­al­ized coun­tries

Evangelisti M., Vitiello E., Campi M. G., Magnano A. C., Ruzzon T.

Isti­tu­to Nazi­o­nale per la Ricer­ca sul Can­cro, Ser­vi­zio Bio­tec­nol­o­gie, Geno­va, Italy


Bio­tech­nol­o­gy, rep­re­sent­ing the ­most prom­is­ing inno­va­tive tech­nol­o­gy for the ­future, is ­able to con­trib­ute to improv­ing the qual­ity of ­life. ­Even ­though it can be ­applied in numer­ous dif­fer­ent sec­tors, it has par­tic­u­lar impor­tance in the bio­med­i­cal ­field. In ­this ­report, we ­shall ­look at the way in ­which bio­tech­nol­o­gy is ­able to con­trib­ute to the ­field of oncol­o­gy, in par­tic­u­lar, for diag­nos­tic and ther­a­py pur­pos­es. In addi­tion, bio­tech­nol­o­gy ­brings ­about ben­e­fits in oth­er sec­tors too, ­like ­those of agri­cul­ture-­food, envi­ron­men­tal pro­tec­tion and chem­i­cals, etc. We ­shall ­present a pano­ram­ic ­view on the devel­op­ment of bio­tech­nol­o­gy in the ­main indus­tri­al­ized Euro­pe­an coun­tries ­whilst refer­ring to oth­er coun­tries in the ­world ­which ­lead in ­this ­area, focus­ing espe­cial­ly on the Unit­ed ­States. We ­shall exam­ine, in par­tic­u­lar, the bio­tech­nol­o­gy devel­op­ment in the Unit­ed King­dom, Ger­ma­ny and ­France, the ­three ­most com­pet­i­tive coun­tries in ­Europe; we ­shall ­also con­sid­er the sit­u­a­tion of bio­tech­nol­o­gy in Ita­ly, a coun­try ­where, ­despite hav­ing to ­still ­make ­progress in the ­field, has ­achieved ­some ­very impor­tant ­results in the ­past few ­years. More­over, the essen­tial fac­tors ­which are ­able to ­favour the devel­op­ment of bio­tech­nol­o­gy, ­which is con­sid­ered by now irre­ver­sible, ­shall be ­looked ­into. ­These fac­tors prin­ci­pal­ly ­regard a ­sound and endur­ing co-oper­a­tion ­between the ­research ­world and indus­tries, ­whose inter­ac­tion ­with one ­another is extreme­ly ­vital in ­order to over­come the exist­ing lim­its and uncer­tain­ties, ­also with­in the ­area of car­ry­ing out tech­nol­o­gy trans­fer. In addi­tion, it is impor­tant to remem­ber the fun­da­men­tal ­need for appro­pri­ate leg­is­la­tive pol­i­cies ­which can ren­der bio­tech­nol­o­gy devel­op­ment sim­pler, ­whilst tak­ing ­into ­account the com­mon Euro­pe­an reg­u­la­tions, not to men­tion the eco­nom­ic incen­tives and tax ­aids for ­those who ­intend on involv­ing them­selves with­in in the bio­tech­nol­o­gy sec­tor. It is ­most impor­tant to not under­es­ti­mate the pub­lic opin­ion on bio­tech­nol­o­gy ­which is ­often one of sus­pi­cion and mis­trust, great­ly influ­enced by the think­ing ­that ­there can be ­more ­health ­risks asso­ciat­ed ­with bio­tech­nol­o­gy ­than actu­al ben­e­fits. How­ev­er, we ­must ­also remem­ber ­that the bio­tech­nol­o­gy ­field is a rel­a­tive­ly ­recent sci­en­tif­ic dis­ci­pline, and so lit­tle is ­known by the pub­lic at ­large and it is some­times ­true ­that, unfor­tu­nate­ly, the ­mass-­media actu­al­ly con­trib­utes neg­a­tive­ly to spread­ing the mis­trust and ambi­gu­ity ­which can sur­round it, ­often pro­vid­ing incor­rect, mis­lead­ing and unre­li­able sourc­es of infor­ma­tion.

top of page

Publication History

Cite this article as

Corresponding author e-mail